Artículos de revistas sobre el tema "EZH2i"
Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros
Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "EZH2i".
Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.
También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.
Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.
Preston, Samuel E. J., Audrey Emond, Filippa Pettersson, Daphné Dupéré-Richer, Madelyn Jean Abraham, Alberto Riva, Mena Kinal et al. "Acquired Resistance to EZH2 Inhibitor GSK343 Promotes the Differentiation of Human DLBCL Cell Lines toward an ABC-Like Phenotype". Molecular Cancer Therapeutics 21, n.º 4 (27 de enero de 2022): 511–21. http://dx.doi.org/10.1158/1535-7163.mct-21-0216.
Texto completoZhang, Yiqun, Lanlan Zhou, Safran Howard, Attila Seyhan y Wafik El-Deiry. "DDRE-16. SYNERGISTIC TUMOR SUPPRESSION FROM COMBINATION OF ONC201 AND EPIGENETIC MODULATORS EZH2 OR HDAC INHIBITOR PROVIDES A NOVEL TREATMENT STRATEGY FOR GBM AND DMG". Neuro-Oncology 22, Supplement_2 (noviembre de 2020): ii64—ii65. http://dx.doi.org/10.1093/neuonc/noaa215.261.
Texto completoKosoff, David, Leigh Ellis, David J. Beebe y Joshua Michael Lang. "Targeting tumor-associated macrophage (TAM) mediated inhibition of T-cell migration in prostate cancer using epigenetic modifying agents." Journal of Clinical Oncology 38, n.º 6_suppl (20 de febrero de 2020): 166. http://dx.doi.org/10.1200/jco.2020.38.6_suppl.166.
Texto completoPawlyn, Charlotte, Michael Bright, Amy Buros, Caleb K. Stein, Zoe Walters, Lauren Aronson, Fabio Mirabella et al. "Inhibition of the Epigenetic Modifier EZH2 Upregulates Cell Cycle Control Genes to Inhibit Myeloma Cell Growth and Overcome High-Risk Disease Features". Blood 128, n.º 22 (2 de diciembre de 2016): 3289. http://dx.doi.org/10.1182/blood.v128.22.3289.3289.
Texto completoSriramkumar, Shruthi, Tara X. Metcalfe, Tim Lai, Xingyue Zong, Fang Fang, Heather M. O’Hagan y Kenneth P. Nephew. "Single-cell analysis of a high-grade serous ovarian cancer cell line reveals transcriptomic changes and cell subpopulations sensitive to epigenetic combination treatment". PLOS ONE 17, n.º 8 (3 de agosto de 2022): e0271584. http://dx.doi.org/10.1371/journal.pone.0271584.
Texto completoCarrancio, Soraya, Celia Fontanillo, Ryan Galasso, Martino Colombo, Scott Wood, Carla Guarinos, Alejandro Panjkovich et al. "Abstract 3932: Pathway interaction and mechanistic synergy of CC-99282, a novel cereblon E3 ligase modulator (CELMoD) agent, with enhancer of zeste homolog 2 inhibitors (EZH2is)". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 3932. http://dx.doi.org/10.1158/1538-7445.am2022-3932.
Texto completoWang, Zhiquan, Justin C. Boysen, Huihuang Yan, Charla R. Secreto, Sameer A. Parikh, Saad S. Kenderian, Wei Ding, Esteban Braggio, Susan L. Slager y Neil E. Kay. "Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia". Blood 136, Supplement 1 (5 de noviembre de 2020): 1. http://dx.doi.org/10.1182/blood-2020-140309.
Texto completoCannito, Sara, Health Biology, Ornella Cutaia, Carolina Fazio, Maria Fortunata Lofiego, Francesca Piazzini, Laura Solmonese, Luana Calabrò, Michele Maio y Alessia Covre. "844 Immunomodulatory activity of epigenetic drugs combinations in mesothelioma: laying the ground for new immunotherapeutic strategies". Journal for ImmunoTherapy of Cancer 8, Suppl 3 (noviembre de 2020): A896. http://dx.doi.org/10.1136/jitc-2020-sitc2020.0844.
Texto completoAoyama, Kazumasa, Makiko Mochizuki-Kashio, Motohiko Oshima, Shuhei Koide, Yaeko Nakajima-Takagi, Mitsutaka Maeda, Goro Sashida y Atsushi Iwama. "Role of the Polycomb Methyltransferase Ezh1 in Myelodysplastic Syndrome Induced By Ezh2 Insufficiency". Blood 128, n.º 22 (2 de diciembre de 2016): 1968. http://dx.doi.org/10.1182/blood.v128.22.1968.1968.
Texto completoTanaka, Satomi, Goro Sashida, Satoru Miyagi, Koutaro Yokote, Chiaki Nakaseko y Atsushi Iwama. "Ezh2 Plays a Critical Role in the Progression of MLL-AF9-Induced Acute Myeloid Leukemia". Blood 118, n.º 21 (18 de noviembre de 2011): 57. http://dx.doi.org/10.1182/blood.v118.21.57.57.
Texto completoVo, Ha V., Qing Zeng, David A. Barbie, Prafulla C. Gokhale, Elizabeth Adams, Cloud P. Paweletz y Elena Ivanova. "Abstract 3264: Ex vivo treatment in high grade serous ovarian cancer demonstrates the benefit of EZH2 inhibition in combination with standard therapy". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 3264. http://dx.doi.org/10.1158/1538-7445.am2022-3264.
Texto completoFiorentino, Francesco Paolo, Irene Marchesi, Christoph Schröder, Ronny Schmidt, Jun Yokota y Luigi Bagella. "BET-Inhibitor I-BET762 and PARP-Inhibitor Talazoparib Synergy in Small Cell Lung Cancer Cells". International Journal of Molecular Sciences 21, n.º 24 (16 de diciembre de 2020): 9595. http://dx.doi.org/10.3390/ijms21249595.
Texto completoFang, Xin, Nan Ni, Xiaofang Wang, Yanan Tian, Ivan Ivanov, Monique Rijnkels, Kayla J. Bayless, John P. Lydon y Qinglei Li. "EZH2 and Endometrial Cancer Development: Insights from a Mouse Model". Cells 11, n.º 5 (7 de marzo de 2022): 909. http://dx.doi.org/10.3390/cells11050909.
Texto completoHasegawa, Nagisa, Goro Sashida, Motohiko Oshima, Hirotaka Matsui, Atsunori Saraya, Changshan Wang, Tomoya Muto, Chiaki Nakaseko, Koutaro Yokote y Atsushi Iwama. "Combinatorial Epigenetic Aberration Propagates in Myelodysplastic Syndrome in the Setting of Concurrent Loss of Tet2 and Ezh2". Blood 126, n.º 23 (3 de diciembre de 2015): 712. http://dx.doi.org/10.1182/blood.v126.23.712.712.
Texto completoMuto, Tomoya, Goro Sashida, Motohiko Oshima, George R. Wendt, Makiko Mochizuki-Kashio, Masashi Sanada, Satoru Miyagi et al. "Concurrent Loss Of Ezh2 and Tet2 Cooperates In The Pathogenesis Of Myelodysplastic Disorders",. Blood 122, n.º 21 (15 de noviembre de 2013): 480. http://dx.doi.org/10.1182/blood.v122.21.480.480.
Texto completoAdamik, Juraj, Jixin Ding, Wei Zhao, Peng Zhang, Quanhong Sun, G. David Roodman y Deborah Lynn Galson. "LIM-Domain Protein Ajuba Is a Required Co-Factor for Gfi1-Induced Epigenetic Switch Regulating Runx2 Repression in Multiple Myeloma-Exposed Pre-Osteoblasts". Blood 126, n.º 23 (3 de diciembre de 2015): 4216. http://dx.doi.org/10.1182/blood.v126.23.4216.4216.
Texto completoZhang, Yiqun, Lanlan Zhou, Howard Safran, Robyn Borsuk, Rishi Lulla, Nikos Tapinos, Attila A. Seyhan y Wafik S. El-Deiry. "EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG". Neoplasia 23, n.º 8 (agosto de 2021): 792–810. http://dx.doi.org/10.1016/j.neo.2021.06.007.
Texto completoSimon, Camille, Jalila Chagraoui, Jana Krosl, Josee Hebert y Guy Sauvageau. "Ezh2 Is An Essential Regulator Of T-Cell Development and Oncogenic Transformation". Blood 122, n.º 21 (15 de noviembre de 2013): 3729. http://dx.doi.org/10.1182/blood.v122.21.3729.3729.
Texto completoHasegawa, Nagisa, Goro Sashida, Motohiko Oshima, Hirotaka Matsui, Changshan Wang, Tomoya Muto, Chiaki Nakaseko, Kotaro Yokote y Atsushi Iwama. "The Biological Function of DNA Hypermethylation in Murine MDS Model Lacking Tet2 and Ezh2". Blood 124, n.º 21 (6 de diciembre de 2014): 4596. http://dx.doi.org/10.1182/blood.v124.21.4596.4596.
Texto completoAdamik, Juraj, Rebecca Silbermann, Konstantinos Lontos, Peng Zhang, Quanhong Sun, Deborah Lynn Galson y G. David Roodman. "EZH2 Inhibitor GSK126 Exhibits Osteo-Anabolic Properties in MM Bone Disease and Synergizes with Bortezomib to Inhibit MM Cell Viability". Blood 128, n.º 22 (2 de diciembre de 2016): 3247. http://dx.doi.org/10.1182/blood.v128.22.3247.3247.
Texto completoGrzenda, Adrienne, Gwen Lomberk, Phyllis Svingen, Angela Mathison, Ezequiel Calvo, Juan Iovanna, Yuning Xiong, William Faubion y Raul Urrutia. "Functional characterization of EZH2β reveals the increased complexity of EZH2 isoforms involved in the regulation of mammalian gene expression". Epigenetics & Chromatin 6, n.º 1 (2013): 3. http://dx.doi.org/10.1186/1756-8935-6-3.
Texto completoHuang, Xian-Ju, Xuguang Wang, Xueshan Ma, Shao-Chen Sun, Xiaolong Zhou, Chengcheng Zhu y Honglin Liu. "EZH2 is essential for development of mouse preimplantation embryos". Reproduction, Fertility and Development 26, n.º 8 (2014): 1166. http://dx.doi.org/10.1071/rd13169.
Texto completoNaimo, Giuseppina Daniela, Maria Elena Gonzalez, Shilpa Reddy Tekula, Jessica Camille Gauss, Loredana Mauro, Sebastiano Andò y Celina Graciela Kleer. "Abstract P5-12-05: Novel pEZH2 T367-PRC2 interaction and methyltransferase activity in the nuclear and cytoplasmic fractions of breast cancer cells". Cancer Research 82, n.º 4_Supplement (15 de febrero de 2022): P5–12–05—P5–12–05. http://dx.doi.org/10.1158/1538-7445.sabcs21-p5-12-05.
Texto completoLi, Boheng, Dennis Kappei, Junli Yan, Pieter Eichhorn, Siok Bian Ng y Wee Joo Chng. "Overexpressed Melk Promotes the Stability of EZH2 through Phosphorylation in Natural Killer/T Cell Lymphoma (NKTL)". Blood 132, Supplement 1 (29 de noviembre de 2018): 2858. http://dx.doi.org/10.1182/blood-2018-99-110758.
Texto completoKotz, Joanne. "EZH2 moves". Science-Business eXchange 5, n.º 41 (octubre de 2012): 1072. http://dx.doi.org/10.1038/scibx.2012.1072.
Texto completoDale, Brandon, Chris Anderson, Kwang-su Park, H. Ümit Kaniskan, Xufen Yu y Jian Jin. "Abstract 2922: Targeting triple negative breast cancer with a VHL recruiting EZH2 protein degrader". Cancer Research 82, n.º 12_Supplement (15 de junio de 2022): 2922. http://dx.doi.org/10.1158/1538-7445.am2022-2922.
Texto completoPapakonstantinou, Nikos, Stavroula Ntoufa, Elisavet Chartomatsidou, Andreas Agathangelidis, Tzeni Karamanli, Achilles Anagnostopoulos, Paolo Ghia, Richard Rosenquist, Chrysoula Belessi y Kostas Stamatopoulos. "Overexpression of the Histone Methyltransferase ΕΖΗ2 in Chronic Lymphocytic Leukemia Confers Protection from Apoptosis and Is Linked to Clinical Aggressiveness". Blood 124, n.º 21 (6 de diciembre de 2014): 1956. http://dx.doi.org/10.1182/blood.v124.21.1956.1956.
Texto completoPerez-Ladaga, Albert, Huafeng Xie, Stuart H. Orkin, David B. Sykes, Benjamin L. Ebert y Rafael Bejar. "Neutrophils Derived from Ezh2 -/- Progenitor Cells Demonstrate Aberrant Erythroid Lineage Gene Expression". Blood 126, n.º 23 (3 de diciembre de 2015): 4112. http://dx.doi.org/10.1182/blood.v126.23.4112.4112.
Texto completoShimizu, Takafumi, Hui Hao-Shen, Lucia Kubovcakova, Pontus Lundberg, Stephan Dirnhofer, Stuart H. Orkin, Jean Grisouard et al. "JAK2V617F and Loss of Ezh2 in Hematopoietic Cells Contribute Synergistically to Myeloproliferative Neoplasm Initiation Potential, and Accelerate Progression of Disease". Blood 124, n.º 21 (6 de diciembre de 2014): 158. http://dx.doi.org/10.1182/blood.v124.21.158.158.
Texto completoBasheer, Faisal, George Giotopoulos, Eshwar Meduri, Haiyang Yun, Milena Mazan, Daniel Sasca, Paolo Gallipoli et al. "Contrasting requirements during disease evolution identify EZH2 as a therapeutic target in AML". Journal of Experimental Medicine 216, n.º 4 (19 de marzo de 2019): 966–81. http://dx.doi.org/10.1084/jem.20181276.
Texto completoBae, An-Na, Soo-Jung Jung, Jae-Ho Lee, Hyunsu Lee y Seung Gyu Park. "Clinical Value of EZH2 in Hepatocellular Carcinoma and Its Potential for Target Therapy". Medicina 58, n.º 2 (20 de enero de 2022): 155. http://dx.doi.org/10.3390/medicina58020155.
Texto completoStomper, Julia, Ruth Meier, Tobias Ma, Dietmar Pfeifer, Annette Schmitt-Graeff y Michael Lübbert. "Integrative Study of EZH2 Mutational Status, Copy Number, Protein Expression and H3K27 Trimethylation in AML/MDS Patients". Blood 134, Supplement_1 (13 de noviembre de 2019): 1422. http://dx.doi.org/10.1182/blood-2019-128231.
Texto completoWei, Yue, Yu Jia, Hong Zheng, Hui Yang, Rui Chen, Hui Wang, Xia Wang y Guillermo Garcia-Manero. "Assessment Of EZH2 Expression In CD34+ Bone Marrow Progenitor Cells Of Patients Of Myelodysplastic Syndromes (MDS)". Blood 122, n.º 21 (15 de noviembre de 2013): 2805. http://dx.doi.org/10.1182/blood.v122.21.2805.2805.
Texto completoSahasrabuddhe, Anagh A., Xiaofei Chen, Thirunavukkarasu Velusamy, Fuzon Chung, Megan S. Lim y Kojo S. J. Elenitoba-Johnson. "A Novel Non-Canonical Phosphodegron Regulates EZH2 Proteasomal Degradation and H3K27 Trimethylation Activity in Hematopoietic Malignancies". Blood 124, n.º 21 (6 de diciembre de 2014): 1678. http://dx.doi.org/10.1182/blood.v124.21.1678.1678.
Texto completoGupta, Mamta, Christos Demosthenous, Mary J. Stenson y Tammy Price-Troska. "Oncogenic Role of Chromatin Modifier Polycomb Repressive Complex-2 in Mantle Cell Lymphoma". Blood 132, Supplement 1 (29 de noviembre de 2018): 1582. http://dx.doi.org/10.1182/blood-2018-99-118957.
Texto completoJiao, Lianying, Murtada Shubbar, Xin Yang, Qi Zhang, Siming Chen, Qiong Wu, Zhe Chen, Josep Rizo y Xin Liu. "A partially disordered region connects gene repression and activation functions of EZH2". Proceedings of the National Academy of Sciences 117, n.º 29 (6 de julio de 2020): 16992–7002. http://dx.doi.org/10.1073/pnas.1914866117.
Texto completoAppelmann, Iris, Claudio Scuoppo, Vishal Thapar, Daniela Ledezma, Amaia Lujambio, Scott W. Lowe y Agustin Chicas. "Suppression of EZH2 Accelerates MYC-Driven Lymphomagenesis By Inhibition of Apoptosis". Blood 124, n.º 21 (6 de diciembre de 2014): 3009. http://dx.doi.org/10.1182/blood.v124.21.3009.3009.
Texto completoChng, Wee-Joo, Junli Yan, Siok-Bian NG, Jim Tay, Baohong Lin, Tze-Loong Koh, Joy Tan et al. "EZH2 Is Aberrantly Expressed and Plays a Pro-Proliferative Role Independent of Its Methyltransferase Activity in Natural Killer/T-Cell Lymphoma". Blood 120, n.º 21 (16 de noviembre de 2012): 3498. http://dx.doi.org/10.1182/blood.v120.21.3498.3498.
Texto completoMochizuki, Daiki, Yuki Misawa, Hideya Kawasaki, Atsushi Imai, Shiori Endo, Masato Mima, Satoshi Yamada, Takuya Nakagawa, Takeharu Kanazawa y Kiyoshi Misawa. "Aberrant Epigenetic Regulation in Head and Neck Cancer Due to Distinct EZH2 Overexpression and DNA Hypermethylation". International Journal of Molecular Sciences 19, n.º 12 (22 de noviembre de 2018): 3707. http://dx.doi.org/10.3390/ijms19123707.
Texto completoSwords, Ronan T., Aymee Perez, Ana Rodriguez, Justin M. Watts, Tino Schenk, Fernando Vargas, Roy Elias y Arthur Zelent. "In Acute Myeloid Leukemia (AML), Targeting the Histone Methyltransferase EZH2 Promotes Differentiation, Impairs Clonogenic Survival and Augments the Anti-Leukemic Effects of the Retinoid, All-Trans-Retinoic Acid (ATRA)". Blood 126, n.º 23 (3 de diciembre de 2015): 3786. http://dx.doi.org/10.1182/blood.v126.23.3786.3786.
Texto completoTomioka, Takahisa, Goro Sashida, Kotaro Shide, Kazuya Shimoda, Naoto Yamaguchi y Atsushi Iwama. "Ezh2 Loss Accelerates JAK2V617F-Driven Primary Myelofibrosis". Blood 122, n.º 21 (15 de noviembre de 2013): 110. http://dx.doi.org/10.1182/blood.v122.21.110.110.
Texto completoBai, Bing, Ying Liu, Xue-Mei Fu, Hai-Yan Qin, Gao-Kai Li, Hai-Chen Wang y Shi-Long Sun. "Dysregulation of EZH2/miR-138-5p Axis Contributes to Radiosensitivity in Hepatocellular Carcinoma Cell by Downregulating Hypoxia-Inducible Factor 1 Alpha (HIF-1α)". Oxidative Medicine and Cellular Longevity 2022 (29 de agosto de 2022): 1–22. http://dx.doi.org/10.1155/2022/7608712.
Texto completoZhang, Xingli, Yan Wang, Jia Yuan, Ni Li, Siyu Pei, Jing Xu, Xuan Luo et al. "Macrophage/microglial Ezh2 facilitates autoimmune inflammation through inhibition of Socs3". Journal of Experimental Medicine 215, n.º 5 (6 de abril de 2018): 1365–82. http://dx.doi.org/10.1084/jem.20171417.
Texto completoMurashima, Akihiro, Keiko Shinjo, Keisuke Katsushima, Tetsuo Onuki, Yasumitsu Kondoh, Hiroyuki Osada, Noritaka Kagaya et al. "Identification of a chemical modulator of EZH2-mediated silencing by cell-based high-throughput screening assay". Journal of Biochemistry 166, n.º 1 (25 de enero de 2019): 41–50. http://dx.doi.org/10.1093/jb/mvz007.
Texto completoXie, Huafeng, Cong Peng, Jun Qi, Giullia Cheloni, Partha Das, Jialiang Huang, Minh Nguyen, Shaoguang Li, James E. Bradner y Stuart H. Orkin. "Eradication of Chronic Myelogenous Leukemia By Inactivation of the Polycomb Group Protein EZH2". Blood 124, n.º 21 (6 de diciembre de 2014): 778. http://dx.doi.org/10.1182/blood.v124.21.778.778.
Texto completoLi, Boheng, Junli Yan, Tae-Hoon Chung, Pei Tsung Lee y Wee Joo Chng. "Mapping the Functional Cofactors of Oncogenic EZH2 in Natural Killer/ T Cell Lymphoma (NKTL)". Blood 128, n.º 22 (2 de diciembre de 2016): 1773. http://dx.doi.org/10.1182/blood.v128.22.1773.1773.
Texto completoIzsak, Allison, Keith Michael Giles, Kevin Paul Lui, Sarah A. Weiss, Una Moran, Eleazar Vega-Saenz de Miera, Jennifer Stein et al. "Targeting EZH2 in acral lentiginous melanoma (ALM)." Journal of Clinical Oncology 35, n.º 15_suppl (20 de mayo de 2017): 9534. http://dx.doi.org/10.1200/jco.2017.35.15_suppl.9534.
Texto completoYang, Yue, Hajime Akada, Dipmoy Nath, Robert E. Hutchison y Golam Mohi. "Loss of EZH2 Inhibits Erythropoiesis and Accelerates the Development of Myelofibrosis in Jak2V617F Knock-in Mice". Blood 124, n.º 21 (6 de diciembre de 2014): 159. http://dx.doi.org/10.1182/blood.v124.21.159.159.
Texto completoJacobsen, Jennifer Andrene, Jennifer Woodard y Barbara L. Kee. "EZH2 regulates cell cycle and survival in B and T lymphocyte progenitors". Journal of Immunology 196, n.º 1_Supplement (1 de mayo de 2016): 122.4. http://dx.doi.org/10.4049/jimmunol.196.supp.122.4.
Texto completoKawabata, Kimihito Cojin, Daichi Inoue, Jiro Kitaura, Yuka Harada, Susumu Goyama, Hironori Harada, Hiroyuki Aburatani y Toshio Kitamura. "A Patient-Derived EZH2 Mutant Induces MDS-like Diseases with Derepressed ABCG2 Expression in Mice". Blood 126, n.º 23 (3 de diciembre de 2015): 4116. http://dx.doi.org/10.1182/blood.v126.23.4116.4116.
Texto completo